Table 4.

Summary of published literature on CLARITY applied to post mortem human brain tissue.

Reference	Age, pathology, fixation	Thickness/brain area/clearing procedure/image analysis	Staining
Chung et al. (2013)	7 y/male/autism	500 μm frontal cortex, Brodmann area 10 active clearing	MBP, parvalbumin neurofilament, GFAP tyrosine hydroxylase
Liu et al. (2016)	Parkinson patient	3 000 μm (imaging up to 771 μm) cerebellum passive clearing	neurofilament Iba-1, α-synuclein tyrosine hydroxylase
Ando et al. (2014)	5 AD patients 2 controls	500 μm frontal cortex passive clearing	anti-tau B19 anti-Aβ 4G8 neurofilament
Phillips et al. (2016)	2 controls 5 mitochondrial disease patients	250 μm cerebellum passive clearing	MBP neurofilament mitochondria COXI Glut-1 α-smooth muscle actin
Costantini et al. (2015)	10 y/child hemimegalencephaly	2000 μm (imaging up to 1 000 μm) passive clearing intracortical fiber tracking for 1 mm	parvalbumin nuclei (DAPI) GFAP
(Leuze et al., 2016)	no information available	500 μm thalamus, passive clearing structural tensor analysis	neurofilament
Current study	54-70 y/3 controls no neurological diseases	8 000 μm transparency, temporal lobe, corpus callosum passive and mild active clearing (imaging 2.5 × 2.5 × 4 mm3) fiber orientation distribution cell classification	MBP, HuC/D, GFAP, ß-III-tubulin, Iba-1, parvalbumin, helix aspersa agglutinin